Lin Lin originally joined the group in January 2015, as a coop student from Northeastern University. Lin developed the SAR on the SOD1 and CMT projects. After graduating from Northeastern, Lin is now back at the LDDN and making key contributions to several projects. In the future, Lin plans to attend medical school.
Priscilla is a student at the University of Huddersfield studying for a MSci in Pharmaceutical Chemistry. Priscilla is spending her placement year here at the LDDN and is focused on the asymmetric synthesis of a number of different heterocycles that increase survival motor neuron protein for the treatment of Spinal Muscular Atrophy.
Dawid originally joined the group in January 2017, as a coop student from Northeastern University.
Dawid is working on the synthesis of analogs in our SMA series that increases transcription of the survival motor neuron protein for the treatment of Spinal Muscular Atrophy. Dawid is also developing water soluble pro-drugs of a poorly soluble drug that we are re-purposing for AD. Dawid plans to go to medical school following graduation.
Akbar grew up in Nepal. He received his MS in Chemistry from Southern Illinois University Edwardsville (SIUE). He worked with Prof. Timothy B. Patrick on method development for the synthesis of fluorinated compounds. Currently he is working in GlaxoSmithKline (GSK), King of Prussia, PA as Scientist Co-op in Drug Design and Selection (DD&S) Medicinal Chemistry. He is a PhD candidate in Organic Chemistry at Iowa State University and worked on method development and total synthesis of natural products. He was advised by Professor Jason S. Chen (currently at Scripps, CA). Akbar will join the LDDN in October as a post-doctoral researcher. In his spare time, Akbar is an amateur photographer.
Dr. Kevin Hodgetts
Director of The Laboratory for Drug Discovery in Neurodegeneration
65 Landsdowne Street
Cambridge, Massachusetts 02139
Kevin has a broad background in organic and medicinal chemistry, with experience in both industrial and academic drug discovery. Kevin spent over 15 years of experience working on treatments for diseases of the central nervous system. Compounds from two projects that he was involved in have entered clinical trials. Kevin joined the LDDN in September 2012, to work with the academic community to design new and innovative strategies for drug discovery for neurodegenerative diseases. Kevin is Assistant Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School. He also co-founded Klogene Therapeutics with Professor Carmela Abraham.